First Allied Advisory Services’s ImmunityBio IBRX Stock Holding History

First Allied Advisory Services’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$84K	Sell	12,184 -679	-5%	-$6.77K	﹤0.01%	1150
2020 Q2	$158K	Buy	12,863 +2,687	+26%	+$15.2K	0.01%	1035
2020 Q1	$29K	Sell	10,176 -5,597	-35%	-$28K	﹤0.01%	1049
2019 Q4	$59K	Hold	15,773	–	–	﹤0.01%	1189
2019 Q3	$19K	Hold	15,773	–	–	﹤0.01%	1474
2019 Q2	$16K	Hold	15,773	–	–	﹤0.01%	1191
2019 Q1	$26K	Buy	15,773 +3,031	+24%	+$3.81K	﹤0.01%	1143
2018 Q4	$14K	Buy	12,742 +2,000	+19%	+$4.58K	﹤0.01%	1068
2018 Q3	$41K	Buy	+10,742	New	+$34K	﹤0.01%	1168
2016 Q1	–	Sell	-17,585	Closed	-$301K	–	1059
2015 Q4	$301K	Buy	+17,585	New	+$261K	0.02%	770

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

First Allied Advisory Services's IBRX Position: Q3 2020 in Review

First Allied Advisory Services reduced its ImmunityBio (IBRX) stake by 5.3% in Q3 2020, selling an estimated $6.77K and leaving 12,184 shares worth $84K. The position accounts for ﹤0.01% of the portfolio, ranked #1150.

First Allied Advisory Services first reported a position in IBRX in Q4 2015 and has held it in 10 quarters since. The position peaked at $301K in Q4 2015. 95 funds tracked by Wall St. Rank hold IBRX as of Q3 2020.

First Allied Advisory Services held 12,184 shares of ImmunityBio worth $84K as of Q3 2020.
First Allied Advisory Services sold 679 ImmunityBio shares in Q3 2020, an estimated $6.77K.
ImmunityBio made up ﹤0.01% of First Allied Advisory Services's portfolio in Q3 2020, its #1150 holding.
First Allied Advisory Services first reported a position in ImmunityBio in Q4 2015 and has held it in 10 quarters since.
First Allied Advisory Services's ImmunityBio position peaked at $301K in Q4 2015.
95 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2020.

Based on First Allied Advisory Services's 13F filing for Q3 2020, filed 13 Nov 2020.